Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Non-Current Debt (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Non-Current Debt for 5 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • Quarterly Non-Current Debt fell 78.36% to $1.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Sep 2025, down 78.36% year-over-year, with the annual reading at $5.1 million for FY2024, 49.24% down from the prior year.
  • Non-Current Debt hit $1.4 million in Q3 2025 for Kezar Life Sciences, down from $2.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $10.1 million in Q4 2023 to a low of $1.4 million in Q3 2025.
  • Historically, Non-Current Debt has averaged $7.8 million across 5 years, with a median of $9.6 million in 2021.
  • Biggest five-year swings in Non-Current Debt: rose 2.39% in 2023 and later tumbled 78.36% in 2025.
  • Year by year, Non-Current Debt stood at $9.6 million in 2021, then rose by 2.2% to $9.8 million in 2022, then rose by 2.39% to $10.1 million in 2023, then plummeted by 49.24% to $5.1 million in 2024, then crashed by 73.12% to $1.4 million in 2025.
  • Business Quant data shows Non-Current Debt for KZR at $1.4 million in Q3 2025, $2.6 million in Q2 2025, and $3.9 million in Q1 2025.